GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Relmada Therapeutics Inc (STU:4E2) » Definitions » Cyclically Adjusted Book per Share

Relmada Therapeutics (STU:4E2) Cyclically Adjusted Book per Share : €2.91 (As of Jun. 2024)


View and export this data going back to 2020. Start your Free Trial

What is Relmada Therapeutics Cyclically Adjusted Book per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

Relmada Therapeutics's adjusted book value per share for the three months ended in Jun. 2024 was €1.893. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is €2.91 for the trailing ten years ended in Jun. 2024.

During the past 12 months, Relmada Therapeutics's average Cyclically Adjusted Book Growth Rate was 10.00% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Book Growth Rate using Cyclically Adjusted Book per Share data.

As of today (2024-09-21), Relmada Therapeutics's current stock price is €3.10. Relmada Therapeutics's Cyclically Adjusted Book per Share for the quarter that ended in Jun. 2024 was €2.91. Relmada Therapeutics's Cyclically Adjusted PB Ratio of today is 1.07.

During the past 11 years, the highest Cyclically Adjusted PB Ratio of Relmada Therapeutics was 2.25. The lowest was 0.00. And the median was 0.00.


Relmada Therapeutics Cyclically Adjusted Book per Share Historical Data

The historical data trend for Relmada Therapeutics's Cyclically Adjusted Book per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Relmada Therapeutics Cyclically Adjusted Book per Share Chart

Relmada Therapeutics Annual Data
Trend Aug13 Jun15 Jun16 Jun17 Jun18 Jun19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted Book per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - 1.69 2.46 2.51

Relmada Therapeutics Quarterly Data
Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24
Cyclically Adjusted Book per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.66 2.76 2.51 2.90 2.91

Competitive Comparison of Relmada Therapeutics's Cyclically Adjusted Book per Share

For the Biotechnology subindustry, Relmada Therapeutics's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Relmada Therapeutics's Cyclically Adjusted PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Relmada Therapeutics's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Relmada Therapeutics's Cyclically Adjusted PB Ratio falls into.



Relmada Therapeutics Cyclically Adjusted Book per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

What is Cyclically Adjusted Book per Share? How do we calculate Cyclically Adjusted Book per Share?

Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Book per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the book value per share from 2001 through 2010.

We adjusted the 2001 book value per share data with the total inflation from 2001 through 2010 to the equivalent book value in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's book value is $1 a share in 2001, then the 2001's equivalent book value in 2010 is $1.4 a share. If Wal-Mart's book value is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 book value in 2010 is $1.35. So on and so forth, you get the equivalent book value per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Relmada Therapeutics's adjusted Book Value per Share data for the three months ended in Jun. 2024 was:

Adj_Book= Book Value per Share /CPI of Jun. 2024 (Change)*Current CPI (Jun. 2024)
=1.893/132.5538*132.5538
=1.893

Current CPI (Jun. 2024) = 132.5538.

Relmada Therapeutics Quarterly Data

Book Value per Share CPI Adj_Book
201409 -7.334 100.428 -9.680
201412 1.388 99.070 1.857
201503 0.858 99.621 1.142
201506 2.913 100.684 3.835
201509 4.477 100.392 5.911
201512 3.600 99.792 4.782
201603 3.050 100.470 4.024
201606 2.083 101.688 2.715
201609 1.650 101.861 2.147
201612 1.473 101.863 1.917
201703 0.870 102.862 1.121
201706 0.415 103.349 0.532
201709 0.392 104.136 0.499
201712 0.194 104.011 0.247
201803 -0.599 105.290 -0.754
201806 -1.504 106.317 -1.875
201809 -2.387 106.507 -2.971
201812 0.169 105.998 0.211
201903 0.054 107.251 0.067
201906 0.691 108.070 0.848
201909 0.546 108.329 0.668
201912 0.000 108.420 0.000
202003 6.854 108.902 8.343
202006 7.408 108.767 9.028
202009 6.409 109.815 7.736
202012 5.314 109.897 6.410
202103 4.571 111.754 5.422
202106 4.602 114.631 5.322
202109 3.530 115.734 4.043
202112 6.644 117.630 7.487
202203 6.497 121.301 7.100
202206 6.202 125.017 6.576
202209 5.866 125.227 6.209
202212 4.405 125.222 4.663
202303 3.893 127.348 4.052
202306 3.414 128.729 3.515
202309 3.136 129.860 3.201
202312 2.600 129.419 2.663
202403 2.197 131.776 2.210
202406 1.893 132.554 1.893

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.


Relmada Therapeutics  (STU:4E2) Cyclically Adjusted Book per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Book per Share may underestimate the company's equity. Cyclically Adjusted PB Ratio can seem to be too high even the actual PB Ratio is low.

For the Cyclically Adjusted PB Ratio, the book value of the past 10 years are inflation-adjusted and averaged. The result is used for P/B calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PB Ratio is also called CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Relmada Therapeutics's Cyclically Adjusted PB Ratio of today is calculated as

Cyclically Adjusted PB Ratio=Share Price/Cyclically Adjusted Book per Share
=3.10/2.91
=1.07

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 11 years, the highest Cyclically Adjusted PB Ratio of Relmada Therapeutics was 2.25. The lowest was 0.00. And the median was 0.00.


Be Aware

Cyclically Adjusted PB Ratio works better for cyclical companies. It gives you a better idea on the company's real book value.


Relmada Therapeutics Cyclically Adjusted Book per Share Related Terms

Thank you for viewing the detailed overview of Relmada Therapeutics's Cyclically Adjusted Book per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Relmada Therapeutics Business Description

Industry
Traded in Other Exchanges
Address
2222 Ponce de Leon Boulevard, Floor 3, Coral Gables, FL, USA, 33134
Relmada Therapeutics Inc is a clinical-stage biotechnology company. It is engaged in developing chemical entities with novel versions of drug products that address areas of high unmet medical need in the treatment of central nervous system diseases. The company is focused on the development of esmethadone (d-methadone, dextromethadone, REL-1017), an N-methyl-D-aspartate (NMDA) receptor antagonist. Its lead product candidate, esmethadone, is an oral agent for the treatment of depression and other potential indications.

Relmada Therapeutics Headlines

No Headlines